Bigger, Further, Longer: Funding And Building The Maturing European Ecosystem


Despite the pandemic, private life sciences investment in Europe has seen strong deal volumes and the US public markets for biotech, in particular, have been booming.

European VCs are raising large new funds across the investment spectrum, from early-stage through to late-stage and crossover funds with large proportions to be invested into European innovation.

How is the investment landscape developing for European life sciences, and the strategies evolving for Europe’s leading VCs?

  • As Europe’s ecosystem develops and matures, are the largest life science backers shifting more towards later stage and crossover strategies? Is the 2020 US IPO bonanza boom affecting investment strategies and portfolio company management?
  • Biotech has been resilient in the capital markets during the crisis, will this growth continue?
  • How are investors advising their portfolio companies to navigate the new normal?

Graham Defries, Partner, Goodwin (moderator)
Regina Hodits, Managing Partner, Wellington Partners Life Sciences
Sander Slootweg, Managing Partner, Forbion
Houman Ashrafian, Managing Partner, SV Health Investors
Hubert Birner, Managing Partner, TVM Capital Life Sciences
Maina Bhaman, Partner, Sofinnova

This session was delivered as part of the Investival Showcase 2020. Find out about the full event by downloading the brochure.